How Effective Is the COVID Vaccine?

🎙️ Voice is AI-generated. Inconsistencies may occur.

Both the COVID-19 vaccine developed by Pfizer and BioNTech, and the one developed by Moderna and the National Institute of Allergy and Infectious Diseases, were found to be around 94 to 95 percent effective in clinical trial settings.

However, further studies will be done to determine how well the vaccines work in real-life settings, the U.S. Centers for Disease Control and Prevention (CDC) has said.

According to a briefing by the Food and Drug Administration (FDA) on the Moderna vaccine, which is under final review on Thursday for emergency us authorization, its "efficacy in preventing confirmed COVID-19 occurring at least 14 days after the second dose of vaccine was 94.5 percent," in a trial involving approximately 30,400 participants.

In an FDA briefing on Pfizer's vaccine, which was approved for emergency use last week, "efficacy in preventing confirmed COVID-19 occurring at least 7 days after the second dose of vaccine was 95.0 percent," in a trial involving about 44,000 people.

The CDC advised last week: "After FDA approves a vaccine or authorizes a vaccine for emergency use, it continues to be studied to determine how well it works under real-world conditions. CDC and other federal partners will be assessing COVID-19 vaccine effectiveness under real-world conditions."

The federal agencies working with the CDC on these latest assessments include the FDA, the Centers for Medicare and Medicaid Services, the Department of Defense, the Indian Health Service and the Veteran's Health Administration.

"These real-world assessments will compare groups of people who do and don't get vaccinated and people who do and don't get COVID-19 to assess how well COVID-19 vaccines are working to protect people," the CDC explained.

Assessments will also be made on how well the vaccines protect people against severe COVID-19 illness, as well as against less severe forms of COVID-19.

The assessments will be done across diverse groups of people, including healthcare personnel, essential workers, older adults, those living in nursing homes, people with underlying medical conditions, different racial and ethnic minority groups as well as tribal nations, the CDC noted.

How COVID-19 vaccines are tested

Experts are working on various types of real-world assessments using different methods including the following, as outlined by the CDC:

Case-control studies

"These assessments will include cases (people who have the virus that causes COVID-19) and controls (people who do not have the virus that causes COVID-19). The people who agree to participate in a case-control assessment will provide information on whether they received a COVID-19 vaccine or not.

Experts will look to see if the cases were less likely to have received the vaccine than controls, which would help show that the vaccine is working.

Test-negative design

"This is a special type of case-control study. These assessments will enroll people who are seeking medical care for symptoms that could be due to COVID-19. Experts will then compare the COVID-19 vaccination status of those who test positive (meaning they have COVID-19) to those who test negative (meaning they do not have COVID-19).

Cohort studies

"These assessments will follow people who have and haven't had a COVID-19 vaccine for several months to see if getting vaccinated protects them from getting the disease. This can be done in real time (prospectively) or by looking back in time (retrospectively) using data that were already collected, such as information in participants' electronic health records (medical records).

Screening method

"These assessments look at vaccination coverage among a group of cases (for example, cases detected through ongoing COVID-19 surveillance) and compares it with vaccination coverage among the overall population where those cases come from (for example people from the same state). By comparing coverage among these two groups, researchers can get an early estimate of whether a vaccine is working as expected.

Ecologic analyses

"These assessments look at groups of people – such as those in different geographic locations or at different times – and find out how many people were vaccinated and how many people were diagnosed with COVID-19. These analyses may be hard to interpret since the number of COVID-19 illnesses has changed rapidly over time and in different places," the CDC noted.

UCLA doctor receives COVID-19 vaccine December 2020
A University of California, Los Angeles (UCLA) doctor being inoculated with the COVID-19 vaccine at the Ronald Reagan UCLA Medical Center in Westwood, California on December 16. The two COVID-19 vaccines developed by Pfizer and... Brian Van Der Brug/Pool/AFP via Getty Images

The wider picture

The novel coronavirus has infected more than 74.2 million people, including over 16.9 million in the U.S., since it was first reported in Wuhan, China.

More than 1.6 million people have died worldwide and over 42 million have recovered as of Thursday, according to John Hopkins University.

The graphic below, provided by Statista, shows the percentage of adults in the U.S. who would or would not get a COVID-19 vaccine.

COVID vaccine hesitancy in U.S.
STATISTA

About the writer

Soo Kim is a Newsweek reporter based in London, U.K. She covers various lifestyle stories, specializing in travel, health, home/interior design and property/real estate. Soo covered the COVID-19 pandemic extensively from 2020 to 2022, including several interviews with the chief medical advisor to the president, Dr. Anthony Fauci. Soo has reported on various major news events, including the Black Lives Matter movement, the U.S. Capitol riots, the war in Afghanistan, the U.S. and Canadian elections, and the 2020 Tokyo Olympics. Soo is also a South Korea expert, covering the latest K-dramas—including the breakout hit Squid Game, which she has covered extensively, including from Seoul, the South Korean capital—as well as Korean films, such as the Golden Globe and Oscar-nominated Past Lives, and K-pop news, to interviews with the biggest Korean actors, such as Lee Jung-jae from Squid Game and Star Wars, and Korean directors, such as Golden Globe and Oscar nominee Celine Song. Soo is the author of the book How to Live Korean, which is available in 11 languages, and co-author of the book Hello, South Korea: Meet the Country Behind Hallyu. Before Newsweek, Soo was a travel reporter and commissioning editor for the award-winning travel section of The Daily Telegraph (a leading U.K. national newspaper) for nearly a decade from 2010, reporting on the latest in the travel industry, from travel news, consumer travel and aviation issues to major new openings and emerging destinations. Soo is a graduate of Binghamton University in New York and the journalism school of City University in London, where she earned a Masters in international journalism. You can get in touch with Soo by emailing s.kim@newsweek.com . Follow her on Instagram at @miss.soo.kim or X, formerly Twitter, at @MissSooKim .Languages spoken: English and Korean


Soo Kim is a Newsweek reporter based in London, U.K. She covers various lifestyle stories, specializing in Read more